Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.080
-0.090 (-2.84%)
Feb 21, 2025, 4:00 PM EST - Market closed
Anixa Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 |
| Net Income | -12.55 | -9.81 | -13.6 | -12.95 | -10.02 | |
| Depreciation & Amortization | 0.04 | 0.05 | 0.04 | 0.06 | 0.09 | |
| Loss (Gain) From Sale of Assets | - | - | - | -0.01 | 0.15 | |
| Stock-Based Compensation | 4.8 | 4.74 | 6.75 | 8.06 | 4.14 | |
| Other Operating Activities | -0.14 | -0.12 | -0.18 | -0.17 | -0.07 | |
| Change in Accounts Receivable | 0.1 | -0.22 | -0.03 | - | 0.06 | |
| Change in Accounts Payable | 0.32 | -0.06 | 0.13 | -0.1 | -0.35 | |
| Change in Other Net Operating Assets | 0.11 | -0.78 | 0.39 | 0.17 | -0.17 | |
| Operating Cash Flow | -7.34 | -6.21 | -6.49 | -4.94 | -6.18 | |
| Capital Expenditures | - | - | - | - | -0.02 | |
| Sale of Property, Plant & Equipment | - | - | - | 0.04 | - | |
| Investment in Securities | 4.28 | -5.6 | -10.73 | -3.96 | -0.29 | |
| Investing Cash Flow | 4.28 | -5.6 | -10.73 | -3.92 | -0.31 | |
| Issuance of Common Stock | 3.42 | 0.37 | 0.45 | 31.57 | 9.41 | |
| Repurchase of Common Stock | -0.01 | - | - | - | - | |
| Financing Cash Flow | 3.42 | 0.37 | 0.45 | 31.57 | 9.41 | |
| Net Cash Flow | 0.36 | -11.45 | -16.77 | 22.71 | 2.93 | |
| Free Cash Flow | -7.34 | -6.21 | -6.49 | -4.94 | -6.19 | |
| Free Cash Flow Margin | - | -2956.67% | - | -964.45% | - | |
| Free Cash Flow Per Share | -0.23 | -0.20 | -0.21 | -0.17 | -0.28 | |
| Levered Free Cash Flow | -3 | -3.02 | -1.26 | 0.04 | -2.64 | |
| Unlevered Free Cash Flow | -3 | -3.02 | -1.26 | 0.04 | -2.64 | |
| Change in Net Working Capital | -0.57 | 1.01 | -0.52 | -0.13 | 0.41 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.